Incyte (INCY) Change in Acquisitions & Divestments (2010 - 2026)
Incyte (INCY) reported Change in Acquisitions & Divestments of $69.7 million for Q1 2026, up 53.21% on a YoY basis from $45.5 million in Q1 2025, and down 7.05% quarter-over-quarter from $75.0 million in Q4 2025.
Incyte (INCY) Change in Acquisitions & Divestments (2010 - 2026) Analysis & Trends
Incyte has reported Change in Acquisitions & Divestments for 17 years, with the latest figure at $69.7 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 53.21% year-over-year to $69.7 million; the trailing twelve-month figure through Mar 2026 stood at $308.8 million (up 76.97% YoY), and the FY2025 full-year result was $284.6 million, up 23.07% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $69.7 million, down from $75.0 million in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $107.8 million in Q3 2025, with the low at $258000.0 in Q1 2022.
- Historically, Change in Acquisitions & Divestments has averaged $57.1 million across 5 years, with a median of $56.3 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments slumped 99.27% — and 2023, when it soared 20515.89%.
- Incyte's Change in Acquisitions & Divestments stood at $21.2 million in 2022, then jumped by 285.38% to $81.6 million in 2023, then tumbled by 71.32% to $23.4 million in 2024, then jumped by 220.63% to $75.0 million in 2025, then declined by 7.05% to $69.7 million in 2026.
- The last three Change in Acquisitions & Divestments figures came in at $69.7 million (Q1 2026), $75.0 million (Q4 2025), and $107.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.70 Mn |
| Mar 31, 2026 | 69.70 Mn |
| Dec 31, 2025 | 74.99 Mn |
| Dec 31, 2025 | 74.99 Mn |
| Sep 30, 2025 | 107.84 Mn |
| Sep 30, 2025 | 107.84 Mn |
| Jun 30, 2025 | 56.31 Mn |
| Jun 30, 2025 | 56.31 Mn |
| Mar 31, 2025 | 45.49 Mn |
| Mar 31, 2025 | 45.49 Mn |
| Dec 31, 2024 | 23.39 Mn |
| Dec 31, 2024 | 23.39 Mn |
| Sep 30, 2024 | 25.25 Mn |
| Sep 30, 2024 | 25.25 Mn |
| Jun 30, 2024 | 80.39 Mn |
| Jun 30, 2024 | 80.39 Mn |
| Mar 31, 2024 | 102.25 Mn |
| Mar 31, 2024 | 102.25 Mn |
| Dec 31, 2023 | 81.56 Mn |
| Dec 31, 2023 | 81.56 Mn |